読み込み中
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
前日終値
$1.25
+$0.07 · +5.93%
日中の時刻はETです。市場データは遅延する場合があります。
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
日中レンジ
現在 $1.25
52週レンジ
現在 $1.25
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
32
割高
センチメント
38
弱気
リスク
48
やや高いリスク
モメンタム
64
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
日中レンジ
現在 $1.25
52週レンジ
現在 $1.25
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 7699.6万 USD | 1.16億 USD | 1.42億 USD | 9840万 USD | 6017万 USD |
| 販売・一般管理 | 2385万 USD | 2609.4万 USD | 2848.3万 USD | 2903.6万 USD | 2338.5万 USD |
| 営業費用 | 1.04億 USD | 1.42億 USD | 1.7億 USD | 1.27億 USD | 8355.5万 USD |
| 受取利息 | 396.4万 USD | 936.6万 USD | 1064.9万 USD | 427.8万 USD | 91 USD |
| 支払利息 | 160.2万 USD | 172.9万 USD | 156.5万 USD | 23.8万 USD | 1.3万 USD |
| 減価償却費と償却費 | 70.6万 USD | 87.2万 USD | 83.6万 USD | 34.2万 USD | 5.1万 USD |
| 営業利益 | −1.04億 USD | −1.42億 USD | −1.7億 USD | −1.27億 USD | −8355.5万 USD |
| 純利益 | −1.02億 USD | −1.35億 USD | −1.61億 USD | −1.23億 USD | −8346.3万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$17.90
上昇余地（1332.00%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI703.07万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM313.36万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF236.63万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO119.96万0.01%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO108.31万0.01%139.17億 USD0.24%$356.78+0.94%
iShares Micro-Cap ETFIWC36.21万0.03%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM26万0.22%1.17億 USD0.73%$15.9402+0.25%
Vanguard Russell 2000 Growth ETFVTWG22.61万0.01%17億 USD0.06%$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
